National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure
- PMID: 2064478
National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure
Abstract
End-stage renal disease attributed to hypertension has increased annually for the last decade and will probably worsen through the year 2000. Patients with diabetic nephropathy and patients with hypertensive renal disease account for most new cases annually. Evidence reveals that all levels of untreated hypertension are associated with potentially declining renal function. Data from the Hypertension Detection and Follow-up Program and other studies show that antihypertensive treatment can prevent progressive renal failure. An ablation model demonstrates glomerular hyperfiltration as a possible mechanism for progressive renal failure. Human data on the renal effects of antihypertensive agents are limited and inconsistent. Despite the limitations, the Working Group on Hypertension and Chronic Renal Failure concludes that controlled hypertension to less than 140/90 mm Hg reduces the incidence of end-stage renal disease. Patients with established renal impairment may benefit from individualized treatment to 130/85 mm Hg or less.
Similar articles
-
Hypertension as a risk factor for progression of chronic renal disease.Blood Press Suppl. 1994;1:23-8. Blood Press Suppl. 1994. PMID: 8205294 Review.
-
1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group.Arch Intern Med. 1996 Sep 23;156(17):1938-47. Arch Intern Med. 1996. PMID: 8823147 Review.
-
Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.Blood Press Suppl. 1995;2:108-12. Blood Press Suppl. 1995. PMID: 7582066 Review.
-
Does essential hypertension cause end-stage renal disease?Kidney Int Suppl. 1992 May;36:S33-7. Kidney Int Suppl. 1992. PMID: 1614065 Review.
-
Epidemiology and prevention of blood pressure-related renal disease.J Hypertens Suppl. 1992 Dec;10(7):S77-84. J Hypertens Suppl. 1992. PMID: 1291660 Review.
Cited by
-
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.Pharmacoeconomics. 1993 Jan;3(1):45-82. doi: 10.2165/00019053-199303010-00006. Pharmacoeconomics. 1993. PMID: 10146987 Review.
-
Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.Clin Pharmacokinet. 1993 Mar;24(3):230-54. doi: 10.2165/00003088-199324030-00005. Clin Pharmacokinet. 1993. PMID: 8462229 Review.
-
Renin inhibitors: cardiovascular drugs of the future?Cardiovasc Drugs Ther. 1996 Jul;10(3):309-12. doi: 10.1007/BF02627954. Cardiovasc Drugs Ther. 1996. PMID: 8877073 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical